Complement activation, endothelin-1 and neuropeptide Y in relation to the cardiovascular response to endotoxin-induced systemic inflammation in healthy volunteers

Acta Anaesthesiologica Scandinavica

Volumn 48, Issue 1, 2004, Pages 74-81

  Soop, A ^a   Albert, J ^b   Weitzberg, E ^a   Bengtsson, A ^d   Lundberg, J O N ^c   Sollevi, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Complement; Endothelin; Endotoxin; Human; Neuropeptide y; Sepsis

Indexed keywords

COMPLEMENT; ENDOTHELIN 1; ENDOTOXIN; NEUROPEPTIDE Y;

ADULT; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; ENDOTOXEMIA; ESCHERICHIA COLI; HEART OUTPUT; HEMODYNAMIC MONITORING; HUMAN; IMMUNOREACTIVITY; MALE; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE;

ADULT; BODY TEMPERATURE; COMPLEMENT ACTIVATION; ENDOTHELIN-1; ENDOTOXEMIA; ENDOTOXINS; HEMODYNAMIC PROCESSES; HUMANS; INFLAMMATION; MALE; NEUROPEPTIDE Y; OXYGEN CONSUMPTION; PULMONARY ALVEOLI; PULMONARY GAS EXCHANGE;

EID: 0346725875     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2004.00273.x     Document Type: Article

References (35)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
2. Murphy K, Haudek SB, Thompson M, Giroir BP. Molecular biology of septic shock. New Horiz 1998; 6: 181-93.
3. Brandtzaeg P, Mollnes TE, Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989; 160: 58-65.
4. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-43.
5. Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 1985; 37: 151-216.
6. Hugli TE. Complement and cellular triggering reactions. Introductory remarks. Fed Proc 1984; 43: 2540-2.
7. Busund R, Balteskard L, Ronning G, Hogasen K, Revhaug A. Fatal myocardial depression and circulatory collapse associated with complement activation induced by plasma infusion in severe porcine sepsis. Acta Anaesthesiol Scand 1995; 39: 100-8.
8. Parker MM, Shelhamer JH, Natanson C, Ailing DW, Parrillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987; 15: 923-9.
9. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1988; 6: S188-91.
10. Miyauchi T, Yanagisawa M, Tomizawa T et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989; 2: 53-4.
11. Mattoli S, Soloperto M, Marini M, Fasoli A. Levels of endothelin in the bronchoalveolar lavage fluid of patients with symptomatic asthma and reversible air flow obstruction. J Allergy Clin Immunol 1991; 88 (3pt1): 376-84.
12. Weitzberg E, Lundberg JM, Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 1991; 33: 222-7.
13. Pernow J, Hemsen A, Lundberg JM. Increased plasma levels of endothelin-like immunoreactivity during endotoxin administration in the pig. Acta Physiol Scand 1989; 137: 317-8.
14. Pittet JF, Morel DR, Hemsen A et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 1991; 213: 261-4.
15. Wanecek M, Oldner A, Sundin P, Alving K, Weitzberg E, Rudehill A. Effects on haemodynamics by selective endothelin ET (B) receptor and combined endothelin ET (A)/ET (B) receptor antagonism during endotoxin shock. Eur J Pharmacol 1999; 386: 235-45.
16. Lundberg JM, Martinsson A, Hemsen A et al. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun 1985; 133: 30-6.
17. Hokfelt T, Broberger C, Zhang X et al. Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system. Brain Res Brain Res Rev 1998; 26: 154-66.
18. Abounader R, Villemure JG, Hamel E. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226. Br J Pharmacol 1995; 116: 2245-50.
19. Hemsen A. Biochemical and functional characterization of endothelin peptides with special reference to vascular effects. Acta Physiol Scand Suppl 1991; 602: 1-61.
20. Theodorsson-Norheim E, Hemsen A, Lundberg JM. Radioimmunoassay for neuropeptide Y (NPY): chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand J Clin Lab Invest 1985; 45: 355-65.
21. Soop A, Sollevi A, Weitzberg E, Lundberg JON, Palm J, Albert J. Exhaled NO and plasma cGMP increase after endotoxin infusion in healthy volunteers. Eur Respir J 2003; 21: 594-9.
22. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-7.
23. Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow EC. Alterations in C3, C4, factor B, and related metabolites in septic shock. Clin Immunol Immunopathol 1993; 69: 136-42.
24. Cooper R. Biology of the complement system 1 in inflammation. In: Gallin JI, Snyderman R, eds. Inflammation: Basic principles and clinical correlates, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 1999; 281-315.
25. Curzen NP, Kaddoura S, Griffiths MJ, Evans TW. Endothelin-1 in rat endotoxemia: mRNA expression and vasoreactivity in pulmonary and systemic circulations. Am J Physiol 1997; 272: H2353-60.
26. Hartemink KJ, Groeneveld AB, de Groot MC, Strack van Schijndel RJ, van Kamp G, Thijs LG. Alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock. Crit Care Med 2001; 29: 80-7.
27. Weitzberg E, Hemsen A, Rudehill A, Modin A, Wanecek M, Lundberg JM. Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol 1996; 118: 617-26.
28. Weitzberg E. Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation. Acta Physiol Scand Suppl 1993; 611: 1-72.
29. Anggard E, Galton S, Rae G et al. The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol 1989; 13: S46-9; discussion S74.
30. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-9.
31. Rudehill A, Olcen M, Sollevi A, Hamberger B, Lundberg JM. Release of neuropeptide Y upon haemorrhagic hypovolaemia in relation to vasoconstrictor effects in the pig. Acta Physiol Scand 1987; 131: 517-23.
32. Qureshi NU, Dayao EK, Shirali S, Zukowska-Grojec Z, Hauser GJ. Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock. Regul Pept 1998; 75-6: 215-20.
33. Corder R, Pralong FP, Muller AF, Gaillard RC. Regional distribution of neuropeptide Y-like immunoreactivity in human hypothalamus measured by immunoradiometric assay: possible influence of chronic respiratory failure on tissue levels. Neuroendocrinology 1990; 51: 23-30.
34. Watson JD, Sury MR, Corder R et al. Plasma levels of neuropeptide tyrosine Y (NPY) are increased in human sepsis but are unchanged during canine endotoxin shock despite raised catecholamine concentrations. J Endocrinol 1988; 116: 421-6.
35. Arnalich F, Sanchez JF, Martinez M et al. Changes in plasma concentrations of vasoactive neuropeptides in patients with sepsis and septic shock. Life Sci 1995; 56: 75-81.